

# Consuelo Huerta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9102227/publications.pdf>

Version: 2024-02-01

50  
papers

2,545  
citations

361296

20  
h-index

189801

50  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3431  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 988-1000.	1.1	19
2	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixabanâ€”A European comparative drug utilization study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 440-454.	1.2	3
3	Drug utilization study on immediate release Fentanyl in Spain. Prevalence, incidence, and indication. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 371-378.	0.9	11
4	BIFAP Program: A Data Resource for Pharmacoepidemiological Research in Spain. <i>Springer Series on Epidemiology and Public Health</i> , 2021, , 165-187.	0.5	0
5	A Validation Study on the Frequency and Natural History of Miscarriages Using the Spanish Primary Care Database BIFAP. <i>Healthcare (Switzerland)</i> , 2021, 9, 596.	1.0	3
6	Use of hydrochlorothiazide and risk of skin cancer in a large nested caseâ€”control study in Spain. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1269-1278.	0.9	12
7	A strategy for assessment and validation of major bleeding cases in a primary health care database in Spain. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1696-1702.	0.9	1
8	Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. <i>Drug Safety</i> , 2021, 44, 383-395.	1.4	26
9	ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling. <i>Vaccine</i> , 2020, 38, B65-B75.	1.7	9
10	ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example. <i>Vaccine</i> , 2020, 38, B22-B30.	1.7	12
11	Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project. <i>Vaccine</i> , 2020, 38, B56-B64.	1.7	10
12	Advance system testing: Vaccine benefit studies using multi-country electronic health data â€” The example of pertussis vaccination. <i>Vaccine</i> , 2020, 38, B31-B37.	1.7	7
13	Impact of preâ€”exposure time bias in selfâ€”controlled case series when the event conditions the exposure: Hip/femur fracture and use of benzodiazepines as a case study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 388-395.	0.9	4
14	ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination. <i>Vaccine</i> , 2020, 38, B38-B46.	1.7	8
15	An algorithm to identify pregnancies in BIFAP Primary Care database in Spain: Results from a cohort of 155Â419 pregnancies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 57-68.	0.9	6
16	Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries â€” The ADVANCE project. <i>Vaccine</i> , 2020, 38, 3243-3254.	1.7	10
17	ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations. <i>Vaccine</i> , 2020, 38, B8-B21.	1.7	17
18	<i>Base de Datos para la InvestigaciÃ³n FarmacoepidemiolÃ³gica en AtenciÃ³n Primaria</i> (<scp>BIFAP</scp>): A data resource for pharmacoepidemiology in Spain. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1236-1245.	0.9	45

#	ARTICLE	IF	CITATIONS
19	ADVANCE system testing: Estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data. <i>Vaccine</i> , 2020, 38, B47-B55.	1.7	3
20	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008â€“2015): A crossâ€“national drug utilization study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2524-2539.	1.1	41
21	The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval. <i>Pharmaceutical Medicine</i> , 2019, 33, 519-530.	1.0	3
22	Estimation of vaccination coverage from electronic healthcare records; methods performance evaluation â€“ A contribution of the ADVANCE-project. <i>PLoS ONE</i> , 2019, 14, e0222296.	1.1	5
23	The recording of human papillomavirus (HPV) vaccination in BIFAP primary care database: A validation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 201-208.	0.9	9
24	Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. <i>Archives of Osteoporosis</i> , 2017, 12, 39.	1.0	14
25	Secular trends of use of anti-osteoporotic treatments in Spain: A population-based cohort study including over 1.5 million people and more than 12 years of follow-up. <i>Bone</i> , 2017, 105, 292-298.	1.4	18
26	A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. <i>Journal of Clinical Epidemiology</i> , 2017, 86, 168-175.	2.4	26
27	Caseâ€“only designs for studying the association of antidepressants and hip or femur fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 103-113.	0.9	11
28	Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related) project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 66-78.	0.9	34
29	Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 88-102.	0.9	23
30	Do caseâ€“only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 79-87.	0.9	12
31	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a crossâ€“national descriptive study from the PROTECTâ€“EU Project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 56-65.	0.9	96
32	Prevalence of antibiotic use: a comparison across various European health care data sources. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 11-20.	0.9	46
33	Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested caseâ€“control studies using two primary care databases in Europe. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 29-38.	0.9	16
34	Methodological comparison of marginal structural model, timeâ€“varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 114-121.	0.9	24
35	Antiepileptic drug use in seven electronic health record databases in Europe: A methodologic comparison. <i>Epilepsia</i> , 2014, 55, 666-673.	2.6	35
36	Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested caseâ€“control study. <i>BMJ Open</i> , 2013, 3, e002091.	0.8	38

#	ARTICLE	IF	CITATIONS
37	Risk of myocardial infarction and overall mortality in survivors of venous thromboembolism. <i>Thrombosis Journal</i> , 2008, 6, 10.	0.9	11
38	Risk Factors and Short-term Mortality of Venous Thromboembolism Diagnosed in the Primary Care Setting in the United Kingdom. <i>Archives of Internal Medicine</i> , 2007, 167, 935.	4.3	344
39	Incidence and Risk Factors for Psoriasis in the General Population. <i>Archives of Dermatology</i> , 2007, 143, 1559-65.	1.7	279
40	Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. <i>American Journal of Kidney Diseases</i> , 2005, 45, 531-539.	2.1	288
41	Respiratory Medications and the Risk of Cardiac Arrhythmias. <i>Epidemiology</i> , 2005, 16, 360-366.	1.2	84
42	Users of oral steroids are at a reduced risk of developing irritable bowel syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 583-588.	0.9	14
43	Risk of Acute Liver Injury in Patients with Diabetes. <i>Pharmacotherapy</i> , 2002, 22, 1091-1096.	1.2	15
44	Risk of Clinical Blood Dyscrasia in a Cohort of Antibiotic Users. <i>Pharmacotherapy</i> , 2002, 22, 630-636.	1.2	26
45	Risk of irritable bowel syndrome among asthma patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 31-35.	0.9	41
46	Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs. <i>Epidemiology</i> , 2001, 12, 88-93.	1.2	342
47	Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study. <i>Epidemiology</i> , 2001, 12, 565-569.	1.2	202
48	Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?. <i>European Journal of Clinical Pharmacology</i> , 2001, 56, 931-933.	0.8	94
49	The risk of obstructive airways disease in a glaucoma population. <i>Pharmacoepidemiology and Drug Safety</i> , 2001, 10, 157-163.	0.9	16
50	Reduced Incidence of Colorectal Adenoma among Long-Term Users of Nonsteroidal Antiinflammatory Drugs: A Pooled Analysis of Published Studies and a New Population-Based Study. <i>Epidemiology</i> , 2000, 11, 376-381.	1.2	129